longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino

MorningStar
Aug 25, 2026 at 11:27 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Intuit shares fell 9.8% after projecting slowing sales growth due to desktop business declines and potential short-term trade-offs for TurboTax. Spyre Therapeutics stock dropped 11% as it deprioritized a rheumatoid arthritis drug candidate following missed trial targets. Zoom Communications shares declined 3.9% after third-quarter EPS guidance missed expectations, while nCino stock fell 5.6% on revenue projections below analyst forecasts.

By Elias Schisgall

 

Intuit projected that sales growth would slow in the year ahead, weighed down by expected declines in the company's desktop business. The company may also accept short-term trade-offs in its business as it looks to boost TurboTax customers, its CFO told The Wall Street Journal. Shares fell 9.8% to $322.57 in after-hours trading on Tuesday.

Spyre Therapeutics said it will not prioritize developing one of its drug candidates as a monotherapy for rheumatoid arthritis after results from a trial missed its internal targets. The stock slid 11% to $95.09 after the bell.

Zoom Communications issued guidance for third-quarter adjusted earnings per share that missed Wall Street expectations. Shares were down 3.9% at $97.00.

NCino projected third-quarter revenue in a range with a midpoint below analyst expectations. The stock was down 5.6% at $19.65.

 

Write to Elias Schisgall at elias.schisgall@wsj.com

 

(END) Dow Jones Newswires

August 25, 2026 19:20 ET (23:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

Login to unlock561characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Jan 27, 2026 at 01:13 PMWill AI accounting be the next "killer" application?
  • Jan 27, 2026 at 02:07 AMInvested $51 million three years ago, now worth $2-4 billion? Anthropic's stake skyrockets, Zoom's stock price surges
  • Aug 19, 2025 at 02:59 AM"Software is dead, AI should rise"?

Related Stocks

Spyre Therapeutics

Spyre Therapeutics

USSYRE

+2.05%

Intuit

Intuit

USINTU

-0.37%

nCino

nCino

USNCNO

-1.38%

LongbridgeAI